title: [Prevalence of psychoactive drug consumption in an obese population].
abstract: OBJECTIVE
  To establish the prevalence of psychoactive drug consumption in an obese population.
  
  
  METHODS
  We collected data from the clinical records of obese patients attending the Endocrinology and Nutrition Department and Psychiatry Department of Hospital del Mar between June 2005 and May 2006 (n=259). We recorded anthropometric, epidemiological and toxicological data. We also investigated the prevalence of concomitant diseases in this population.
  
  
  RESULTS
  Psychoactive drugs were consumed by 37% of obese patients, mainly antidepressants (27%), anxiolytics, sedatives and hypnotics, and anticonvulsants. Moreover, 15% of all patients received combination treatment with two or more psychoactive drugs, mostly the association of an antidepressant and an antiepileptic drug.
  
  
  CONCLUSIONS
  The prevalence of psychoactive drug consumption in our sample was higher than prevalence data observed in the general population, with antidepressant consumption being three-fold higher.
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitari Arnau de Vilanova de Lleida, Universitat de Lleida, Lleida, España. dbtafalla@gmail.com
authors.forename: Maria A
authors.initials: MA
authors.lastname: Cerdá Esteve
authors.forename: Diego
authors.initials: D
authors.lastname: Barral Tafalla
authors.forename: Mindaugas
authors.initials: M
authors.lastname: Gudelis
authors.forename: Albert
authors.initials: A
authors.lastname: Goday
authors.forename: Magi
authors.initials: M
authors.lastname: Farre Albaladejo
authors.forename: Juan F
authors.initials: JF
authors.lastname: Cano
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000453:epidemiology; D015897:Comorbidity; D003863:Depression / Q000188:drug therapy / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D004363:Drug Utilization / Q000706:statistics & numerical data; D004827:Epilepsy / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology* / Q000523:psychology; D010003:Osteoarthritis / Q000453:epidemiology; D019338:Polypharmacy; D015995:Prevalence; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D013030:Spain / Q000453:epidemiology
chemical_list: D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D006993:Hypnotics and Sedatives; D011619:Psychotropic Drugs